Endometriosis Market Positioned for Accelerated Development Through 2034, DelveInsight Finds

The endometriosis market was valued at approximately USD 2,300 million in 2023 and is projected to grow at a robust CAGR during the forecast period (2025–2034). DelveInsight's comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the endometriosis landscape.

By analyzing historical data, current market dynamics, and future projections, DelveInsight equips pharmaceutical companies, investors, and healthcare professionals with actionable intelligence to make informed strategic decisions, identify investment opportunities, optimize product positioning, and plan research and development initiatives effectively.

The endometriosis market is increasingly guided by novel hormone-modulating strategies. Oral gonadotropin-releasing hormone (GnRH) receptor antagonists represent a rapidly expanding biomarker segment, highlighted by treatments like elagolix and linzagolix. Elagolix has established itself as a market-leading therapy, with FDA approval received in 2018, while newer agents continue to reshape the competitive landscape with enhanced efficacy and safety profiles.

DelveInsight's report, "Endometriosis Market Insights, Epidemiology, and Market Forecast-2034," provides a comprehensive analysis of the endometriosis landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

Additionally, it examines endometriosis market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To know in detail about the endometriosis market outlook, drug uptake, treatment scenario and epidemiology trends, visit Endometriosis Market Forecast

Key Facts of the Endometriosis Market Report

• Key endometriosis companies include AbbVie, Bayer, Pfizer, Myovant Sciences/Sumitomo Pharma, Organon, Eli Lilly, Teva Pharmaceutical Industries, Kissei Pharmaceutical, Mithra Pharmaceuticals, Gesynta Pharma, Jiangsu Hengrui Medicine Co., Ferring, TiumBio, Lisata Therapeutics, and others
• Key endometriosis therapies include Elagolix (Orilissa/Oriahnn), MYFEMBREE (relugolix combination), Linzagolix (Yselty), Estelle, Vipoglanstat, SHR7280, Quinagolide, HMI-115, VR103, Ovarest, MRX1, TU2670, IW-3300, AMY-109, VML 0501, OG-6219, Teverelix trifluoroacetate, Raviset, VAL301, Nibrozetone, TTX334e, IntraVagS302, IntraVagS301, FP-300, and others.
• The endometriosis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage endometriosis pipeline products will significantly revolutionize the endometriosis market dynamics.

Endometriosis Overview

Endometriosis is a chronic gynecological condition characterized by the presence of endometrial-like tissue outside the uterus. It is estimated to affect approximately 10% of women of reproductive age worldwide. The condition presents with diverse clinical manifestations, including severe menstrual pain (dysmenorrhea), chronic pelvic pain, painful sexual intercourse (dyspareunia), and infertility. Endometriosis is often diagnosed at an advanced stage and may be driven by hormonal and immunological dysregulation, making hormone-modulating therapies and pain management strategies important treatment options. Risk factors include delayed childbearing, delayed pregnancy, genetic predisposition, and environmental exposures. Early detection through advanced imaging and molecular diagnostics, combined with personalized treatment approaches, improves patient outcomes and quality of life.

Key Trends in Endometriosis Therapeutics Market

• Shift to Oral GnRH Antagonists: Increasing adoption of oral gonadotropin-releasing hormone receptor antagonists, offering convenient once-daily dosing with improved efficacy compared to traditional hormonal therapies
• Precision Medicine and Biomarker-Driven Approaches: Enhanced understanding of endometriosis pathophysiology enabling targeted therapeutic strategies and stratified patient populations
• Combination Therapies: Development of fixed-dose combinations incorporating hormone modulators with estradiol and progestin add-back therapy to balance efficacy and safety
• Improved Diagnostic Technologies: Advancement in non-invasive imaging techniques and molecular biomarkers enabling earlier diagnosis and better patient stratification
• Pipeline Innovation: Robust development of next-generation GnRH antagonists, aromatase inhibitors, selective progesterone receptor modulators, and other novel mechanisms to address unmet needs
• Digital Health Integration: Use of digital therapeutics, telemedicine, and patient-centric mobile health solutions to optimize treatment management and quality of life monitoring

Endometriosis Epidemiology

The report on endometriosis epidemiology provides a comprehensive analysis of the disease's prevalence, incidence, and patient demographics. It includes age- and gender-specific distribution, regional and global trends, and data on disease severity and staging. The report also highlights risk factors, disease burden, and projections for future trends, helping stakeholders understand the scope of endometriosis and plan targeted interventions, research, and treatment strategies.

Endometriosis Epidemiology Segmentation

The endometriosis market report provides epidemiological analysis for the study period 2025–2034 in the 7MM segmented into:

• Endometriosis prevalent cases, 
• Diagnosed prevalent cases of Endometriosis
• Age-specific diagnosed prevalent cases of Endometriosis
• Diagnosed Endometriosis prevalent cases by pain severity, 
• Total treated cases of endometriosis

Download the report to understand which factors are driving endometriosis epidemiology trends @ Endometriosis Epidemiology Forecast

Recent Developments in the Endometriosis Treatment Landscape

• In April 2025, AstraZeneca announced the completion of a USD 1.3 billion investment in its global R&D center in Cambridge, UK, which includes a dedicated research unit for endometriosis
• In August 2025, the FDA granted breakthrough therapy designation to rinatabart sesutecan (Rina-S) for treatment of adult patients with recurrent or progressive endometrial cancer who progressed after platinum-containing therapy and PD-(L)1 treatment.
• In January 2025, Gesynta Pharma raised about USD 29 million to accelerate clinical development of its innovative non‑hormonal treatment for endometriosis, positioned as a safer, long‑term option without hormone‑related side effects.
• In January 2025, Linzagolix received European Commission approval for endometriosis-associated pain (EAP), marking a significant milestone for the oral GnRH antagonist class in addressing the unmet needs of women with endometriosis. The product is not yet approved in the United States but commercial launches have begun across several EU member states, led by Theramex in collaboration with Kissei.
• In May 2024, TiumBio Co., Ltd. announced positive topline results from its Phase 2a clinical trial of Merigolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in patients with moderate to severe endometriosis-associated pain. These results support the potential of GnRH antagonists in addressing the significant unmet medical need in endometriosis treatment.​

Endometriosis Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of potential drugs recently launched in the endometriosis market or expected to get launched during the study period. The analysis covers endometriosis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers endometriosis pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

To know more about endometriosis companies working in the treatment market, visit @ Endometriosis Clinical Trials and Therapeutic Assessment

Endometriosis Market Drivers

• Increasing prevalence of endometriosis globally, with estimated 190 million women affected worldwide, driving demand for effective therapies.
• Rising awareness and advocacy initiatives improving disease recognition and diagnosis rates across populations.
• Growth of novel oral gonadotropin-releasing hormone (GnRH) receptor antagonists offering superior efficacy and tolerability profiles compared to traditional therapies.
• Advancements in diagnostic technologies and imaging modalities enabling earlier and more accurate disease identification.
• Rising healthcare expenditure and government initiatives supporting women's health and reproductive medicine.
• Expanding clinical trial pipeline with 15+ active companies developing 20+ potential therapies addressing unmet needs.
• Development of combination therapies with add-back hormone therapy improving patient outcomes and quality of life.

Endometriosis Market Barriers

• High cost of novel therapies limiting patient access, particularly in resource-limited settings and emerging markets.
• Complex clinical trial designs and lengthy regulatory approval processes delaying treatment availability.
• Diagnostic delay averaging 7-10 years from symptom onset to confirmed diagnosis, impacting early intervention opportunities.
• Limited awareness and accessibility of advanced treatments in emerging markets and underserved populations.
• Side effects and safety concerns associated with long-term hormone therapy, particularly bone mineral density loss.
• Cultural stigma surrounding gynecological conditions limiting patient advocacy and help-seeking behavior.
• Variability in patient response due to heterogeneous disease pathophysiology and genetic factors.

Scope of the Endometriosis Market Report

• Study Period: 2025–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Endometriosis Companies: AbbVie, Bayer, Pfizer, Myovant Sciences/Sumitomo Pharma, Organon, Eli Lilly, Teva Pharmaceutical Industries, Kissei Pharmaceutical, Mithra Pharmaceuticals, Gesynta Pharma, Jiangsu Hengrui Medicine Co., Ferring, TiumBio, Lisata Therapeutics, and othersresearchandmarkets+3​
• Key Endometriosis Therapies: Elagolix, MYFEMBREE, Linzagolix, Estelle, Vipoglanstat, SHR7280, Quinagolide, HMI-115, VR103, Ovarest, MRX1, TU2670, IW-3300, AMY-109, VML 0501, OG-6219, Teverelix trifluoroacetate, Raviset, VAL301, Nibrozetone, TTX334e, IntraVagS302, IntraVagS301, FP-300, and otherstrial.medpath+2​
• Endometriosis Therapeutic Assessment: Endometriosis current marketed and endometriosis emerging therapies
• Endometriosis Market Dynamics: Endometriosis market drivers and endometriosis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Endometriosis Unmet Needs, KOL's views, Analyst's views, Endometriosis Market Access and Reimbursement

Discover more about therapies set to grab major endometriosis market share @ Endometriosis Treatment Market